5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT
5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme


5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login
5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Healthcare vs Nifty

Healthcare
Nifty Benchmark
5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme


5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login

Stocks in this sector

S.No.Name
1.Horizon Industrial Parks Ltd.Business ServicesBusiness Support16,02656—1.94290%3.30%-7.20%10
2.Syngene International Ltd.Business ServicesBusiness Support15,50938370.203.311170.33%9.50%6.70%10
3.Indegene Ltd.Business ServicesBusiness Support13,90457834.703.381330.39%18.90%14.10%2
4.Sun Pharma Advanced Research Company Ltd.Business ServicesBusiness Support6,39119642.78410%163.90%276.90%1
5.Leap India Ltd.Business ServicesBusiness Support6,20914499.605.23280%9.30%9.70%1
6.EKI Energy Services Ltd.Business ServicesBusiness Support19769—0.451310%-3.90%-4.30%10

Headlines

Latest news for this sector

  1. 1IPC conference in Bengaluru focuses on biosimilar safety, standardsThe News Mill · 1 day ago
  2. 2Health Ministry's Indian Pharmacopoeia Commission holds national conference in Bengaluru to strengthen safety and standards of biosimilar medicinesANI News · 2 days ago
  3. 3Alembic Pharma clears USFDA inspection at Vadodara bioequivalence facilityBusiness Standard · 2 days ago
  4. 4Lupin to Market Pegfilgrastim Biosimilar in IndiaNAVLIN DAILY · 3 days ago
  5. 5Dr. Reddy's Expands Semaglutide Portfolio With Oral Biosimilar Launch in India and Generic Injection in Canadascanx.trade · 4 days ago
  6. 6Lupin gets marketing approval for Pegfilgrastim biosimilar in Indiapharma.economictimes.indiatimes.com · 4 days ago
  7. 7Scoop: Air India to issue a stern warning letter to Kapil Sharma for his misbehaviorIMDb · 7 days ago
  8. 8Cohance Lifesciences completes USFDA inspection with four observationsBusiness Upturn · 8 days ago
  9. 9Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilarThe Economic Times · 9 days ago
  10. 10Cipla’s Invagen partners Qilu for Keytruda biosimilar in USIndian Pharma Post · 9 days ago

Sub Industries

5 sub-industries
S.No.
1.Business Support6658,34245,41877.85%77.85%38.373.0931.412.8552.303.0479.830.62149.32%49.32%33.50%0.62-34.63%—0.5870.220—-33.02%0.12%332.51%—
2.Hospital & Healthcare Services44447,45,9043,22,40243.22%43.22%91.697.8270.405.5147.655.23107.400.49120.97%20.97%5.00%0.4921.02%—0.8435.700—13.34%0.22%166.29%—
3.Medical Equipment/Supplies/Accessories121239,91135,91789.99%89.99%70.567.5441.784.9828.603.76115.750.27119.13%19.13%20.27%0.2718.87%—0.8986.020—4.33%0.29%-22.87%—
4.Miscellaneous13135,3274,47984.08%84.08%2,1883.9990.922.8211.352.5584.460.16110.76%10.76%12.69%0.16-1,724%—0.8851.030—0.13%0.02%-60.92%—
5.Pharmaceuticals & Drugs14014028,43,3778,78,76730.91%30.91%53.556.5736.134.33352.77230.900.12113.55%13.55%16.87%0.12-40.90%17.10%0.8584.380.012.85%11.37%0.39%142.90%-4.74%

Healthcare

Sector overview
Total Companies
215
Total Market Cap (₹ Cr)
36,92,861
Top 3 Market Cap (₹ Cr)
8,78,767
Sector Concentration
23.80%
Weighted P/E
64.28
Weighted P/B
6.77
Avg Dividend Yield
0.32%
Avg Qtrly Profit Growth (YoY)
143.74%
Avg Qtrly Sales Growth (YoY)
-4.74%
Avg Sector ROE
16.28%
Avg Sector ROCE
14.87%
Avg Debt to Equity
0.22
Broad Industries
3
Sub Industries
5

AI Sector View

AI GENERATED
Buy
Currency 95.23 (Sep/26)Inflation Rate 4.45% (Jul/26)Consumer Spending INR 44743 billion (Jun/26)sector FPI flow net_3m INR 10620 crore (2026-08-31)

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%